# A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

> clinical trial · VERIFIED · 2026-07-27

Status: NOT_YET_RECRUITING · Sponsor: UCB Biopharma SRL · Condition: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

- Company: UCB Biopharma SRL
- Sector: biotech
- Primary source: https://clinicaltrials.gov/study/NCT07725939

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.